Tesaro Garners $101,000,000 Series B Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ae77edee-f1ae-427c-a5a8-1283f02e917a&Preview=1 - Date
6/21/2011 - Company Name
Tesaro - Mailing Address
135 Clarendon St. Boston, MA 02116 - Company Description
TESARO is a privately held oncology-focused biopharmaceutical company whose passionate associates are dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products. - Website
http://www.tesarobio.com - Transaction Type
Venture Equity - Transaction Amount
$101,000,000 - Transaction Round
Series B - Proceeds Purposes
TESARO plans to develop one or more compounds for oncology indications, including the treatment of patients with non-small cell lung cancer (NSCLC) whose tumors express an ALK fusion protein; recent clinical proof-of-concept has been demonstrated for ALK inhibition in this patient population. The Series B financing will fund further development of these programs and expansion of the pipeline. - M&A Terms
- Venture Investor
Kleiner Perkins Caufield & Byers - Venture Investor
InterWest Partners - Venture Investor
New Enterprise Associates - Venture Investor
New Enterprise Associates - Venture Investor
Pappas Ventures - Venture Investor
Deerfield Capital - Venture Investor
Undisclosed
